therapeutic autologous dendritic cells
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
Synaffix Expands ADC Licensing Partnerships with Boehringer Ingelheim and Mitsubishi Tanabe
Synaffix, Boehringer Ingelheim, Mitsubishi Tanabe, ADC technology, oncology, cancer treatment, licensing agreement
Roche’s Chugai Enters $780M Deal with Swiss ADC Specialist Araris Biotech
Roche, Chugai, Araris Biotech, ADC, Antibody-Drug Conjugate, Biotech Deal
GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC
GSK, DualityBio, ADC, Preclinical, Biotech, Pharmaceutical Partnerships
Gilead Partners with Tubulis for Solid Tumor ADC Development in Deal Worth Up to $465M
Gilead, Tubulis, ADC, Solid Tumor, Biotech, Partnership
Adcendo Secures $135M for ADC Pipeline Development
Adcendo, ADC pipeline, funding, biotech, cancer treatment, clinical trials
Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline
Adcendo, Novo Holdings, ADC pipeline, funding, biotech, antibody-drug conjugate
Pyxis Oncology Faces Setback as Early ADC Readout in Solid Tumors Fails to Impress
Pyxis Oncology, ADC, PYX-201, solid tumors, clinical trial, stock performance
IDEAYA Advances Cancer Pipeline with Biocytogen’s Bispecific ADC, Targeting B7H3/PTK7
IDEAYA, Biocytogen, Bispecific ADC, B7H3/PTK7, Cancer Pipeline, Precision Medicine Oncology